Stephanie Pollock

I am a Clinical Trial Coordinator working on OPTiMISE-X, SHIP, and most recently the OPTIMISE2 trial - investigating anti-hypertensive medication reduction in over 75s at risk of serious adverse events.

I have been part of the Oxford PC-CTU since May 2022. 

Originally from Montreal, Canada, I have over 10 years research experience in both industry and academic settings. 

Following a postdoctoral fellowship at the University of Oxford, Antiviral Drug Discovery Unit, I took on the role of HCV Project Leader for United Therapeutics (Chertsey, UK) followed by R&D Scientist and Project Manager for ProImmune Ltd. (Oxford, UK). My D.Phil work in the Department of Biochemistry, University of Oxford, focused on the development of liposome-based antiviral therapies, mainly for the treatment of HIV and HCV.